Page 35 - Primary Biliary Cholangitis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Primary biliary cholangitis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Primary Biliary Cholangitis Today - Breaking & Trending Today

Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients

HANGZHOU, China and SHAOXING, China, Feb. 14, 2022 /PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672) today announces that Shanghai Public Health Clinical Center initiated functional cure study of anti-PD-L1 antibody ASC22 (Envafolimab) in combination with Chidamide in patients infected by human immunodeficiency virus (HIV) with antiviral suppression. The objective of this study (ClinicalTrials.gov Identifier: NCT05129189) is to evaluate the. ....

Hong Kong , Jun Chen , Jinzij Wu , Chipscreen Biosciences , Lu Xianping , Shanghai Public Health Clinical Center , Ascletis Bioscience Co Ltd , Hong Kong Stock Exchange , Prnewswire Ascletis Pharma Inc , Shenzhen Chipscreen Biosciences Co Ltd , Deputy Chief Physician , General Manager , Hepatitisb Virus , Primary Biliary Cholangitis ,

Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries

HANGZHOU, China and SHAOXING, China, Feb. 13, 2022 /PRNewswire/ Ascletis Pharma Inc. today announces that it has submitted marketing authorization applications for ritonavir in. | February 13, 2022 ....

United States , Hong Kong , United Kingdom , Paxlovid Nirmatrelvir , China National Medical Products Administration , Hong Kong Stock Exchange , Ascletis Pharma Inc , Ascletis Pharma , North America , Asian Pacific , Hepatitisb Virus , Primary Biliary Cholangitis , Ascletis Pharma Inc Stock Exchange , Press Release , Itonavir 1672 Kyg0520k1094 ,

Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries

/PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted marketing authorization applications for ritonavir (100 mg film-coated. ....

United States , Hong Kong , United Kingdom , Paxlovid Nirmatrelvir , China National Medical Products Administration , Hong Kong Stock Exchange , Ascletis Pharma Inc , Ascletis Pharma , North America , Asian Pacific , Hepatitisb Virus , Primary Biliary Cholangitis , Ascletis Pharma Inc ,

Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries

/PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted marketing authorization applications for ritonavir (100 mg film-coated. ....

United States , Hong Kong , United Kingdom , Paxlovid Nirmatrelvir , China National Medical Products Administration , Hong Kong Stock Exchange , Ascletis Pharma Inc , Ascletis Pharma , North America , Asian Pacific , Hepatitisb Virus , Primary Biliary Cholangitis , Ascletis Pharma Inc ,

Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors

/PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672) announces today the approval of the Investigational New Drug (IND) application by U.S. Food and Drug. ....

Hong Kong , Jinzij Wu , Hong Kong Stock Exchange , Drug Administration , Ascletis Pharma Inc , Prnewswire Ascletis Pharma Inc , Investigational New Drug , Hepatitisb Virus , Primary Biliary Cholangitis , Ascletis Pharma Inc ,